1. Home
  2. SHPH vs VIVS Comparison

SHPH vs VIVS Comparison

Compare SHPH & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.07

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.90

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHPH
VIVS
Founded
2012
2007
Country
United States
United States
Employees
N/A
13
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
5.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
SHPH
VIVS
Price
$1.07
$1.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
192.3K
2.5M
Earning Date
05-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$1.42
52 Week High
$5.59
$5.30

Technical Indicators

Market Signals
Indicator
SHPH
VIVS
Relative Strength Index (RSI) 34.09 48.61
Support Level $0.14 $1.75
Resistance Level $2.00 $2.20
Average True Range (ATR) 0.13 0.23
MACD -0.04 -0.01
Stochastic Oscillator 3.70 18.52

Price Performance

Historical Comparison
SHPH
VIVS

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: